Capricor Therapeutics Inc (CAPR)

[Volcano]

CAPR Key points:
1. 100% efficient for 6 COVID-19 acute respiratory distress syndrome (ARDS)

2. FDA approved it to treat up 20 additional COVID-19 patients. ( the test may finish in one month)

3. CAP-1002 are very efficient --- effect in one to four days and no adverse effect

4. CAP-1002 have demonstrated favorable modulation of various inflammatory cytokins and regular the immune response. Which is the key to cure the later COVID-19 patients.

5, CAP-1002 has applaied to 150 patients which showed it is a novel mechanism of GAME CHANGE help COVID-19

6, Next event: CAP-1002 for Duchenne muscular dystrophy (DMD) data will be publish in mid-May 2002